Two Sigma Securities LLC acquired a new stake in shares of Tesaro (NASDAQ:TSRO) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,074 shares of the biopharmaceutical company’s stock, valued at approximately $255,000.
Other large investors have also recently modified their holdings of the company. Exane Derivatives raised its stake in shares of Tesaro by 137.1% during the fourth quarter. Exane Derivatives now owns 1,942 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 1,123 shares during the last quarter. Toronto Dominion Bank increased its position in shares of Tesaro by 244.6% during the third quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,130 shares during the period. Bourgeon Capital Management LLC purchased a new position in shares of Tesaro during the fourth quarter valued at about $211,000. Fox Run Management L.L.C. purchased a new position in shares of Tesaro during the fourth quarter valued at about $218,000. Finally, Commonwealth Equity Services Inc purchased a new position in shares of Tesaro during the third quarter valued at about $222,000.
Several equities analysts recently issued reports on the stock. Piper Jaffray reiterated a “hold” rating and set a $65.00 price target on shares of Tesaro in a research report on Thursday, January 18th. Wells Fargo reiterated an “outperform” rating and set a $122.00 price target (down previously from $224.00) on shares of Tesaro in a research report on Wednesday, February 28th. BidaskClub upgraded shares of Tesaro from a “strong sell” rating to a “sell” rating in a research report on Tuesday, March 6th. HC Wainwright reiterated a “buy” rating and set a $108.00 price target on shares of Tesaro in a research report on Tuesday, March 27th. Finally, Royal Bank of Canada reduced their price target on shares of Tesaro to $48.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and fourteen have given a buy rating to the company. Tesaro currently has a consensus rating of “Buy” and a consensus price target of $129.26.
In other news, VP Grant C. Bogle sold 1,809 shares of the company’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $54.85, for a total value of $99,223.65. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director David M. Mott bought 68,302 shares of the company’s stock in a transaction dated Friday, March 2nd. The stock was purchased at an average price of $55.56 per share, for a total transaction of $3,794,859.12. Following the purchase, the director now owns 12,825 shares of the company’s stock, valued at approximately $712,557. The disclosure for this purchase can be found here. In the last quarter, insiders bought 334,913 shares of company stock worth $19,083,294 and sold 13,042 shares worth $760,526. Corporate insiders own 40.50% of the company’s stock.
TSRO traded down $1.76 during midday trading on Friday, reaching $54.70. The company’s stock had a trading volume of 1,500,111 shares, compared to its average volume of 843,683. The stock has a market cap of $2,984.65, a PE ratio of -5.97 and a beta of 1.34. The company has a debt-to-equity ratio of 1.75, a quick ratio of 4.39 and a current ratio of 4.74. Tesaro has a 1 year low of $52.20 and a 1 year high of $168.92.
Tesaro (NASDAQ:TSRO) last announced its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.39) by ($0.96). The business had revenue of $48.02 million during the quarter, compared to analysts’ expectations of $51.78 million. Tesaro had a negative return on equity of 126.44% and a negative net margin of 222.15%. equities research analysts predict that Tesaro will post -9.46 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Two Sigma Securities LLC Takes $255,000 Position in Tesaro (TSRO)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/08/two-sigma-securities-llc-invests-255000-in-tesaro-inc-tsro-stock.html.
Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.
Receive News & Ratings for Tesaro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro and related companies with MarketBeat.com's FREE daily email newsletter.